Tarenflurbil: a shot on goal

被引：12

作者：

Aisen, Paul S. ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA

来源：

LANCET NEUROLOGY | 2008年 / 7卷 / 06期

关键词：

D O I：

10.1016/S1474-4422(08)70091-7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：468 / 469

页数：2

共 7 条

[1] The development of anti-amyloid therapy for Alzheimer's disease - From secretase modulators to polymerisation inhibitors
Aisen, PS
[J]. CNS DRUGS, 2005, 19 (12) : 989 - 996
[2] Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, Randall J.
Munsell, Ling Y.
Morris, John C.
Swarm, Robert
Yarasheski, Kevin E.
Holtzman, David M.
[J]. NATURE MEDICINE, 2006, 12 (07) : 856 - 861
[3] NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, JL
Sagi, SA
Smith, TE
Weggen, S
Das, P
McLendon, DC
Ozols, VV
Jessing, KW
Zavitz, KH
Koo, EH
Golde, TE
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) : 440 - 449
[4] Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase
Siemers, Eric R.
Dean, Robert A.
Friedrich, Stuart
Ferguson-Sells, Lisa
Gonzales, Celedon
Farlow, Martin R.
May, Patrick C.
[J]. CLINICAL NEUROPHARMACOLOGY, 2007, 30 (06) : 317 - 325
[5] A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S
Eriksen, JL
Das, P
Sagi, SA
Wang, R
Pietrzik, CU
Findlay, KA
Smith, TE
Murphy, MP
Butler, T
Kang, DE
Marquez-Sterling, N
Golde, TE
Koo, EH
[J]. NATURE, 2001, 414 (6860) : 212 - 216
[6] Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (vol 7, pg 483, 2008)
Wilcock, G. K.
Black, S. E.
Hendrix, S. B.
Zavitz, K. H.
Swabb, E. A.
Laughlin, M. A.
[J]. LANCET NEUROLOGY, 2011, 10 (04) : 297 - 297
[7] γ-secretase:: Structure, function, and modulation for Alzheimer's disease
Wolfe, Michael S.
[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (01) : 2 - 8

← 1 →